Clinical TrialMay 19, 2026, 08:51 AM
IceCure ProSense® Kidney Cancer Cryoablation 89.4% Recurrence-Free Rate
AI Summary
IceCure Medical announced strong clinical data for its ProSense® cryoablation technology, presented at ECIO 2026. The ICESECRET trial showed an 89.4% recurrence-free rate for kidney cancer tumors 3 cm, with 83.9% recurrence-free at a median 4.0 years. Additionally, independent studies reported no residual early-stage breast cancer at 6 and 12 months with 100% excellent cosmetic outcomes, and a 92.9% fibroadenoma volume reduction at 12 months post-treatment. The company noted growing global momentum and interest in breast cryoablation, with a dedicated course at ECIO being overbooked.
Key Highlights
- ProSense® achieved an 89.4% recurrence-free rate for kidney cancer tumors 3 cm.
- 83.9% of kidney cancer patients remained recurrence-free at a median 4.0 years follow-up.
- Early-stage breast cancer study reported no residual disease at 6 and 12 months.
- 100% of breast cancer patients reported excellent cosmetic outcomes.
- Fibroadenoma study showed 92.9% volume reduction at 12 months post-treatment.
- First-ever dedicated breast cryoablation course at ECIO 2026 was overbooked.
- ICESECRET trial involved 114 patients and 138 procedures for small renal masses.
Price Impact
More from ICCM